Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is a publicly traded Healthcare sector company. As of September 21, 2026, RXRX trades at $3.93 with a market cap of $2.05B and a P/E ratio of -3.79. RXRX moved +0.13% today. Year to date, RXRX is -6.36%; over the trailing twelve months it is -22.31%. Its 52-week range spans $2.77 to $12.36. Analyst consensus is buy with an average price target of $6.43. Rallies surfaces RXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for RXRX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $3.93 |
| Market Cap | $2.05B |
| P/E Ratio | -3.79 |
| EPS | $-1.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.36 |
| 52-Week Low | $2.77 |
| Volume | 8.80M |
| Avg Volume | 0 |
| Revenue (TTM) | $54.85M |
| Net Income | $-518.88M |
| Gross Margin | 3.49% |
5 analysts cover RXRX: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.43.